Introduction
Despite advances in the treatment of classical Hodgkin lymphoma (CHL), current therapies fail to cure 10-15% of patients, and a similar proportion of patients may be over-treated, resulting in both short-term and long-term treatment-related complications. The International Prognostic Factors Project Score (IPS) is the current gold standard used to risk-stratify patients with advanced stage CHL, but its power to identify patients in whom treatment is likely to fail in the modern treatment era has weakened. [1] [2] [3] Robust biomarkers are thus needed to better risk-stratify patients at diagnosis.
In CHL, the malignant Hodgkin 4 Tumorassociated macrophages (TAMs) were shown to be associated with inferior outcomes in CHL. 5 Steidl et al. showed a macrophage gene expression signature to be associated with primary treatment failure in CHL and subsequently showed, using an independent validation cohort, that increased CD68 immunohistochemistry (IHC) expression was associated with inferior outcomes, including outcome after salvage treatment with autologous stem cell transplantation. 6 Since then most [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , but not all 12, [18] [19] [20] , subsequent studies
For personal use only. on April 30, 2017 . by guest www.bloodjournal.org From have confirmed the inferior prognostic significance of tumor-associated macrophages in CHL using CD68 and/or CD163 IHC. In addition, early interim PET analysis after two courses of chemotherapy has prognostic value in advanced stage CHL and increased CD68 IHC expression was recently shown to be associated with a higher rate of early PET positivity. 8 However,
there has been variability in suggested threshold values for CD68 and CD163
IHC expression in the literature. This variability may reflect differences in IHC quantitation methodology between studies, the use of manual visual scoring techniques and lack of subsequent validation of thresholds in their respective studies. In addition, studies thus far represent retrospective single institution experiences.
We address these current issues in our study by investigating the prognostic significance of TAMs using CD68 and CD163 IHC in the E2496 Intergroup trial, a large multicentre phase III randomized controlled clinical trial comparing ABVD and Stanford V chemotherapy. We employ an objective method of quantitating CD68 and CD163 IHC expression using computer image analysis (Aperio Technologies, California, USA), and establish optimum thresholds for CD68 and CD163 IHC expression using X-tile software that is based on the maximal chi-squared value of the log rank test for overall survival in a training cohort. These thresholds are then tested in a separate independent validation cohort. 
In situ hybridization for Epstein Barr Virus (EBV)-encoded RNA (EBER ISH)
EBER ISH was performed using the INFORM EBER probe (Ventana). Slides were also stained on an automated stainer (Ventana Benchmark XT) using the Ventana ISH/iView Blue detection kit. A known positive control was used.
Nuclear staining in Hodgkin-Reed-Sternberg (HRS) cells was considered positive.
Immunohistochemistry scoring
CD68 and CD163 IHC were analyzed by computer image analysis (Aperio Technologies, California, USA) and pathologist scoring (visual, KLT). Statistical analyses were performed using SPSS software (version 14.0). Two-sided p values less than 0.05 were considered statistically significant.
The statistical software X-tile (version 3.6.1) 22 was used to randomly assign patients into training and validation cohorts, as mentioned previously. X-tile was also used to determine the thresholds for CD68 and CD163 IHC expression, by selecting the maximal chi-squared values of the log-rank test for overall survival between two groups, designated as low-and high-risk.
These thresholds were then carried forward and tested in the independent validation cohort.
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Results

Patients' characteristics
There were no significant differences between the subset of cases available for correlative studies (n = 287) and those not available from the total clinical trial cohort (n = 507, giving a total of 794 patients) (Supplemental Table 1 ), suggesting that these cases were representative of the entire patient population. There were also no significant differences in patient characteristics between training and validation cohorts. (Table 1) 
CD68 expression
Using the optimum threshold of 12.7% obtained with X-tile 89 patients had low CD68 expression (≤12.7%, CD68 
Increased CD68 or CD163 expression is a significant independent predictor of inferior outcome
Univariate and multivariate analyses were performed on the validation cohort.
On univariate analysis, stage IV disease, low lymphocyte count, increased CD68 and CD163 expression were significantly associated with inferior FFS.
Increased age, increased CD68 and CD163 expression were significantly associated with inferior OS. (Table 4) In order to determine whether CD68 or CD163 were independently associated with outcomes, respectively, two separate multivariate analyses were performed, including the factors significantly associated with FFS or OS in univariate analysis. These analyses demonstrated that increased CD68 or CD163 expression were significant independent predictors of inferior FFS and OS. (Table 4) For
Discussion
We confirm the prognostic significance of tumor-associated macrophages in IHC expression to be associated with inferior outcome in CHL. 16 However, they reported this method to be labor intensive. 16 We used Aperio
Technologies for computer image analysis to assess CD68 and CD163 IHC.
In addition, we attempted to produce robust thresholds for CD68 and CD163
IHC expression by developing optimum thresholds based on the maximal chisquared values of the log-rank test for overall survival in a training cohort, and then testing these thresholds in a separate independent validation cohort.
Aperio was able to analyze tissue cores in their entirety, with scores averaged from both cores of the same patient to provide a more representative score for each case, within the limitations of a tissue microarray. In addition, Aperio is a user friendly system and shows potential for application on whole tissue sections. Compared to CD68, CD163 appeared to show an overall crisper and stronger intensity of staining and a cleaner background in our hands, making it more ideal for analysis by Aperio's Positive Pixel Count algorithm. This experience with the quality of CD163 IHC is in agreement with other investigators. 19, 20 In addition, the KP1 clone for CD68 has been reported to be a less specific marker for macrophages as it is also known to react with myeloid and fibroblastic cells, 23 while clone 10D6 for CD163 has been reported to be more specific than both KP1 and PGM1 clones for CD68 in identifying macrophages. 24 For these reasons, CD163 may be a better marker for identifying TAMs than CD68. We also showed increased CD68 and CD163 expression to be associated with increased age, EBER positivity and mixed cellularity subtype of CHL. 16, 20, 35 Indeed, a gene expression profiling study showed overexpression of genes associated with either histiocytes or T cells, including CD68 and CD163, in EBV-positive CHL compared to EBV-negative CHL. 36 Despite an association with increased CD68 and CD163 expression in EBER pos cases, no survival differences were seen with regards to EBER status in our study. 
